| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| M-A Crocq, V Camus, B Millet, J Gliskman, J-M Azorin, M-O Krebs, F Limosin, J Costentin, J Dalér. [Clinical potentialities and perspectives for the use of aripiprazole in other disorders than its classical indications. A critical analysis of the recent literature]. L'Encephale. vol 34. issue 2. 2008-09-09. PMID:18597728. |
aripiprazole is indicated for the treatment of schizophrenia in europe and the united states, and for bipolar disorders in the latter. |
2008-09-09 |
2023-08-12 |
Not clear |
| John W Newcomer, Joao Alberto Campos, Ronald N Marcus, Christopher Breder, Robert M Berman, Wendy Kerselaers, Gilbert J L'italien, Marleen Nys, William H Carson, Robert D McQuad. A multicenter, randomized, double-blind study of the effects of aripiprazole in overweight subjects with schizophrenia or schizoaffective disorder switched from olanzapine. The Journal of clinical psychiatry. vol 69. issue 7. 2008-09-09. PMID:18605811. |
a multicenter, randomized, double-blind study of the effects of aripiprazole in overweight subjects with schizophrenia or schizoaffective disorder switched from olanzapine. |
2008-09-09 |
2023-08-12 |
human |
| John W Newcomer, Joao Alberto Campos, Ronald N Marcus, Christopher Breder, Robert M Berman, Wendy Kerselaers, Gilbert J L'italien, Marleen Nys, William H Carson, Robert D McQuad. A multicenter, randomized, double-blind study of the effects of aripiprazole in overweight subjects with schizophrenia or schizoaffective disorder switched from olanzapine. The Journal of clinical psychiatry. vol 69. issue 7. 2008-09-09. PMID:18605811. |
this multicenter, randomized, double-blind study compared the metabolic effects of aripiprazole versus olanzapine in overweight persons with schizophrenia or schizoaffective disorder who were previously on olanzapine treatment. |
2008-09-09 |
2023-08-12 |
human |
| Gerhard Gründer, Christine Fellows, Hildegard Janouschek, Tanja Veselinovic, Christian Boy, Anno Bröcheler, Katrin M Kirschbaum, Sandra Hellmann, Katja M Spreckelmeyer, Christoph Hiemke, Frank Rösch, Wolfgang M Schaefer, Ingo Vernaleke. Brain and plasma pharmacokinetics of aripiprazole in patients with schizophrenia: an [18F]fallypride PET study. The American journal of psychiatry. vol 165. issue 8. 2008-09-04. PMID:18381901. |
brain and plasma pharmacokinetics of aripiprazole in patients with schizophrenia: an [18f]fallypride pet study. |
2008-09-04 |
2023-08-12 |
Not clear |
| Gerhard Gründer, Christine Fellows, Hildegard Janouschek, Tanja Veselinovic, Christian Boy, Anno Bröcheler, Katrin M Kirschbaum, Sandra Hellmann, Katja M Spreckelmeyer, Christoph Hiemke, Frank Rösch, Wolfgang M Schaefer, Ingo Vernaleke. Brain and plasma pharmacokinetics of aripiprazole in patients with schizophrenia: an [18F]fallypride PET study. The American journal of psychiatry. vol 165. issue 8. 2008-09-04. PMID:18381901. |
in order to further characterize its extrastriatal and time-dependent binding characteristics, the authors conducted positron emission tomography (pet) studies with the d(2)/d(3) antagonist [(18)f]fallypride at varying time points after the last aripiprazole administration in patients with schizophrenia. |
2008-09-04 |
2023-08-12 |
Not clear |
| Jae Seung Chang, Yong Min Ahn, Hye Jean Park, Kyu Young Lee, Se Hyun Kim, Ung Gu Kang, Yong Sik Ki. Aripiprazole augmentation in clozapine-treated patients with refractory schizophrenia: an 8-week, randomized, double-blind, placebo-controlled trial. The Journal of clinical psychiatry. vol 69. issue 5. 2008-09-03. PMID:18370574. |
aripiprazole augmentation in clozapine-treated patients with refractory schizophrenia: an 8-week, randomized, double-blind, placebo-controlled trial. |
2008-09-03 |
2023-08-12 |
Not clear |
| Jae Seung Chang, Yong Min Ahn, Hye Jean Park, Kyu Young Lee, Se Hyun Kim, Ung Gu Kang, Yong Sik Ki. Aripiprazole augmentation in clozapine-treated patients with refractory schizophrenia: an 8-week, randomized, double-blind, placebo-controlled trial. The Journal of clinical psychiatry. vol 69. issue 5. 2008-09-03. PMID:18370574. |
this randomized, double-blind, placebo-controlled study evaluated the efficacy and safety of aripiprazole augmentation in clozapine-treated patients with refractory schizophrenia. |
2008-09-03 |
2023-08-12 |
Not clear |
| Lawrence Blonde, Hong J Kan, Elane M Gutterman, Gilbert J L'Italien, Myoung S Kim, Linda Hanssens, Robert D McQuad. Predicted risk of diabetes and coronary heart disease in patients with schizophrenia: aripiprazole versus standard of care. The Journal of clinical psychiatry. vol 69. issue 5. 2008-09-03. PMID:18435564. |
predicted risk of diabetes and coronary heart disease in patients with schizophrenia: aripiprazole versus standard of care. |
2008-09-03 |
2023-08-12 |
Not clear |
| Lawrence Blonde, Hong J Kan, Elane M Gutterman, Gilbert J L'Italien, Myoung S Kim, Linda Hanssens, Robert D McQuad. Predicted risk of diabetes and coronary heart disease in patients with schizophrenia: aripiprazole versus standard of care. The Journal of clinical psychiatry. vol 69. issue 5. 2008-09-03. PMID:18435564. |
in clinical trials, effects on metabolic parameters with aripiprazole are similar to those with placebo and superior to those with olanzapine, and the schizophrenia trial of aripiprazole (star) demonstrated comparable efficacy of aripiprazole versus standard of care (soc; physicians' selection of quetiapine, olanzapine, or risperidone). |
2008-09-03 |
2023-08-12 |
Not clear |
| Richard S E Keefe, Anil K Malhotra, Herbert Y Meltzer, John M Kane, Robert W Buchanan, Anita Murthy, Mindy Sovel, Chunming Li, Robert Goldma. Efficacy and safety of donepezil in patients with schizophrenia or schizoaffective disorder: significant placebo/practice effects in a 12-week, randomized, double-blind, placebo-controlled trial. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. vol 33. issue 6. 2008-08-07. PMID:17625502. |
in total, 250 patients (18-55 years) with schizophrenia or schizoaffective disorder who were clinically stabilized on risperidone, olanzapine, quetiapine, ziprasidone, or aripiprazole, alone or in combination, were enrolled at 38 outpatient psychiatric clinics in the united states. |
2008-08-07 |
2023-08-12 |
Not clear |
| F Limosin, J M Azorin, M O Krebs, B Millet, J Glikman, V Camus, M A Crocq, J Costentin, J Dalér. [Present data and treatment schedule of aripiprazole in the treatment of schizophrenia]. L'Encephale. vol 34. issue 1. 2008-07-15. PMID:18514155. |
[present data and treatment schedule of aripiprazole in the treatment of schizophrenia]. |
2008-07-15 |
2023-08-12 |
Not clear |
| F Limosin, J M Azorin, M O Krebs, B Millet, J Glikman, V Camus, M A Crocq, J Costentin, J Dalér. [Present data and treatment schedule of aripiprazole in the treatment of schizophrenia]. L'Encephale. vol 34. issue 1. 2008-07-15. PMID:18514155. |
five short-term efficacy studies, conducted on 1648 patients presenting with schizophrenia or acute relapse of schizoaffective disorders, demonstrated the greater efficacy of aripiprazole than the placebo and comparable efficacy to that of haloperidol and risperidone. |
2008-07-15 |
2023-08-12 |
Not clear |
| F Limosin, J M Azorin, M O Krebs, B Millet, J Glikman, V Camus, M A Crocq, J Costentin, J Dalér. [Present data and treatment schedule of aripiprazole in the treatment of schizophrenia]. L'Encephale. vol 34. issue 1. 2008-07-15. PMID:18514155. |
aripiprazole is effective on all the dimensions of schizophrenia: the positive and negative and depressive and anxious symptomatology. |
2008-07-15 |
2023-08-12 |
Not clear |
| Mark Sanford, Lesley J Scot. Intramuscular aripiprazole : a review of its use in the management of agitation in schizophrenia and bipolar I disorder. CNS drugs. vol 22. issue 4. 2008-07-10. PMID:18336061. |
intramuscular aripiprazole : a review of its use in the management of agitation in schizophrenia and bipolar i disorder. |
2008-07-10 |
2023-08-12 |
Not clear |
| Mark Sanford, Lesley J Scot. Intramuscular aripiprazole : a review of its use in the management of agitation in schizophrenia and bipolar I disorder. CNS drugs. vol 22. issue 4. 2008-07-10. PMID:18336061. |
an intramuscular formulation of the atypical antipsychotic aripiprazole (abilify) has been developed and is approved in the eu for use in agitation and disturbed behaviour associated with schizophrenia. |
2008-07-10 |
2023-08-12 |
Not clear |
| Mark Sanford, Lesley J Scot. Intramuscular aripiprazole : a review of its use in the management of agitation in schizophrenia and bipolar I disorder. CNS drugs. vol 22. issue 4. 2008-07-10. PMID:18336061. |
intramuscular aripiprazole was more effective than placebo in these patient populations and was noninferior to intramuscular haloperidol in those with agitation associated with schizophrenia and its related disorders. |
2008-07-10 |
2023-08-12 |
Not clear |
| Martin Desseilles, Fernand Mathot, Michel Desseille. Aripiprazole diminishes cannabis use in schizophrenia. The Journal of neuropsychiatry and clinical neurosciences. vol 20. issue 1. 2008-07-02. PMID:18305305. |
aripiprazole diminishes cannabis use in schizophrenia. |
2008-07-02 |
2023-08-12 |
Not clear |
| Rajnish Mag. Proposed strategies for successful clinical management with aripiprazole. Expert opinion on pharmacotherapy. vol 9. issue 8. 2008-06-19. PMID:18473703. |
aripiprazole is an effective medication for treating patients with schizophrenia and bipolar disorder , and as an adjunct in patients with major depressive disorder and an inadequate response to antidepressant treatment, that is generally safe and well tolerated. |
2008-06-19 |
2023-08-12 |
Not clear |
| R E Nordquist, C Risterucci, J L Moreau, M von Kienlin, B Künnecke, M Maco, C Freichel, C Riemer, W Spoore. Effects of aripiprazole/OPC-14597 on motor activity, pharmacological models of psychosis, and brain activity in rats. Neuropharmacology. vol 54. issue 2. 2008-05-12. PMID:18054053. |
aripiprazole (opc-14597) is an antipsychotic with a unique pharmacology as a dopamine d2 receptor partial agonist, which has been demonstrated to reduce symptoms of schizophrenia. |
2008-05-12 |
2023-08-12 |
rat |
| J Bhattacharjee, H G G El-Saye. Aripiprazole versus typicals for schizophrenia. The Cochrane database of systematic reviews. issue 1. 2008-04-14. PMID:18254107. |
aripiprazole versus typicals for schizophrenia. |
2008-04-14 |
2023-08-12 |
Not clear |